Moderna On Tuesday, it said its vaccine, which targets respiratory syncytial virus, is effective in preventing disease in older people.
The vaccine was 83.7% effective in preventing lower respiratory tract disease, defined as two or more symptoms, in people over the age of 60, according to a Boston biotech company. The prevention effect for lower respiratory tract diseases he had three or more symptoms was 82.4%.
According to Moderna, no safety concerns have been identified during clinical trials of the vaccine. The company said the safety and efficacy data from the trial will be published in a peer-reviewed journal. The clinical trial has enrolled approximately 37,000 people in 22 countries.
Moderna said it plans to file for approval by the Food and Drug Administration in the first half of this year. There is currently no FDA-approved vaccine for him against RSV.
A woman receives a moderna coronavirus disease (COVID-19) booster vaccine at an immunization center in Antwerp, Belgium, February 1, 2022.
Johanna Gelon | Reuters
Moderna shares are up about 7% in long-term trading.
According to the Centers for Disease Control and Prevention, RSV infection kills 6,000 to 10,000 older people and hospitalizes 60,000 to 120,000 people each year.
Last fall, the United States experienced an unusually severe RSV season among children and the elderly as the public largely stopped enforcing public health measures such as masks and social distancing implemented in response to the COVID-19 pandemic. was hit by
Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s successful Covid injection. The Covid vaccine has turned Moderna into a global name and windfall profits, but it remains the company’s only commercial product and demand is waning.
Boston biotech companies face increasing pressure to prove that other products in their pipeline can successfully enter the market. Morgan Stanley estimates the market for his RSV vaccine in adults at $7 billion to $10 billion.
